Fibroblast growth factor (FGF) is a class of more than 20 members of the cytokine family, has a variety of physiological functions to promote cell proliferation, body development, angiogenesis, wound repair. Different ways, mainly through local role in most FGF, FGF-19, FGF21 fibroblast Growth factor 21 and FGF-23 showed endocrine factor activity in metabolic regulation process, thanks to the fracture of the β-clover area it has a weak heparin-binding ability, and helps to spread to other sites to play a role. FGF-21 plays an important role in the regulation of glucose and lipid metabolism in the ascendant, it is expected to become a clinical drug for the treatment of type 2 diabetes.

FGF-21 in metabolic diseases is becoming the academia the new hot spot. Since 2005, doubling year after year, the number of research papers on the FGF-21FGF21 fibroblast Growth factor 21, but the understanding of its mechanism of action is still in its infancy. Many basic scientific questions remain to be answered. There are several different forms of FGF-21 is in the early stages of clinical research, FGF-21 in vitro studies of the structure and function has also made ​​great progress, and of FGF-21 pharmacological effects in animal tests showed good consistency and repeatability. More importantly, the test has been confirmed the TZD can affect FGF21 fibroblast Growth factor 21 and its receptor expression, indicating that such drugs may partially through FGF-21 signaling pathway, anti-diabetic effect. In addition, although the pharmacological effects of FGF-21 is powerful, but some animals may be presence of FGF21 fibroblast Growth factor 21 resistance, and therefore to develop more potent agonist FGF-21 will help to overcome the potential of FGF-21 resistance. Ongoing clinical trials, and the deepening of the basic research for the development on metabolic disease have therapeutic value FGF-21 agonists provide a reliable basis.

Hide Comments | Add Comment